Literature DB >> 7354106

Sample size considerations for non-randomized comparative studies.

R W Makuch, R M Simon.   

Abstract

Mesh：

Year:  1980        PMID： 7354106     DOI： 10.1016/0021-9681(80)90017-x

Source DB:  PubMed          Journal:  J Chronic Dis        ISSN： 0021-9681


× No keyword cloud information.
  12 in total

1.  Calculating sample size in trials using historical controls.

Authors:  Song Zhang; Jing Cao; Chul Ahn
Journal:  Clin Trials       Date:  2010-06-23       Impact factor: 2.486

2.  Frontline treatment of localized osteosarcoma without methotrexate: results of the St. Jude Children's Research Hospital OS99 trial.

Authors:  Najat C Daw; Michael D Neel; Bhaskar N Rao; Catherine A Billups; Jianrong Wu; Jesse J Jenkins; Juan Quintana; Lori Luchtman-Jones; Milena Villarroel; Victor M Santana
Journal:  Cancer       Date:  2011-01-10       Impact factor: 6.860

3.  Survival trial design and monitoring using historical controls.

Authors:  Jianrong Wu; Xiaoping Xiong
Journal:  Pharm Stat       Date:  2016-06-15       Impact factor: 1.894

4.  Sample size considerations for historical control studies with survival outcomes.

Authors:  Hong Zhu; Song Zhang; Chul Ahn
Journal:  J Biopharm Stat       Date:  2015-06-22       Impact factor: 1.051

5.  A phase II study of VEPA/FEPP chemotherapy for aggressive lymphoma in elderly patients: Japan Clinical Oncology Group Study JCOG9203.

Authors:  Fumi Mizoroki; Yuko Hirose; Masayuki Sano; Haruhiko Fukuda; Kensei Tobinai; Masanobu Nakata; Masafumi Taniwaki; Fumio Kawano; Kimiharu Uozumi; Kenichi Sawada; Shiro Fukuhara; Kaori Nasu; Yoichiro Ohno; Hironobu Toki; Atsushi Togawa; Masahiro Kikuchi; Tomomitsu Hotta; Masanori Shimoyama
Journal:  Int J Hematol       Date:  2006-01       Impact factor: 2.490

6.  Phase II cancer clinical trials with heterogeneous patient populations.

Authors:  Sin-Ho Jung; Myron N Chang; Sun J Kang
Journal:  J Biopharm Stat       Date:  2012       Impact factor: 1.051

Review 7.  A comparison of phase II study strategies.

Authors:  Sally Hunsberger; Yingdong Zhao; Richard Simon
Journal:  Clin Cancer Res       Date:  2009-09-29       Impact factor: 12.531

8.  Maintenance of Sorafenib following combined therapy of three-dimensional conformal radiation therapy/intensity-modulated radiation therapy and transcatheter arterial chemoembolization in patients with locally advanced hepatocellular carcinoma: a phase I/II study.

Authors:  Jian-Dong Zhao; Jin Liu; Zhi-Gang Ren; Ke Gu; Zhen-Hua Zhou; Wen-Tao Li; Zhen Chen; Zhi-Yong Xu; Lu-Ming Liu; Guo-Liang Jiang
Journal:  Radiat Oncol       Date:  2010-02-12       Impact factor: 3.481

9.  Supplemental immunoglobulin (ivIgG) treatment in 163 patients with sepsis and septic shock--an observational study as a prerequisite for placebo-controlled clinical trials.

Authors:  G Pilz; S Kääb; G Neeser; I Class; U Schweigart; A Brähler; O Bujdoso; R Neumann; K Werdan
Journal:  Infection       Date:  1991 Jul-Aug       Impact factor: 3.553

10.  Group sequential design for historical control trials using error spending functions.

Authors:  Jianrong Wu; Yimei Li
Journal:  J Biopharm Stat       Date:  2019-11-12       Impact factor: 1.051
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.